Is it appropriate to reduce the frequency of tralokinumab in patients who respond to the medication?
Featuring Tina Bhutani, MD, MAS |
Associate Professor, Department of Dermatology
University of California
San Francisco, CA
Related Media
Powered by Polaris TM